Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL

NAUnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

March 31, 2022

Conditions
Chronic Lymphocytic Leukemia
Interventions
DIAGNOSTIC_TEST

COVID-19 serology

Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).

Trial Locations (2)

31048

RECRUITING

Bnai Zion Medical Center, Haifa

Unknown

RECRUITING

Hematology Division, Chaim Sheba Medical Center, Tel Aviv

All Listed Sponsors
collaborator

Ziv Medical Center

OTHER

collaborator

Hadassah Medical Organization

OTHER

collaborator

Ben-Gurion University of the Negev

OTHER

collaborator

Galilee Medical Center

UNKNOWN

collaborator

Kaplan Medical Center

OTHER

collaborator

Meir Medical Center

OTHER

collaborator

Soroka University Medical Center

OTHER

collaborator

Rambam Health Care Campus

OTHER

collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Rabin Medical Center

OTHER

collaborator

Sourasky Medical Center

UNKNOWN

lead

Bnai Zion Medical Center

OTHER_GOV